Gazyva 1000mg Injection

About

Obinutuzumab (Gazyva) is a humanized monoclonal antibody that targets the CD20 protein found on the surface of B-cells. It works by binding to CD20, leading to direct cell death, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC), thereby depleting malignant B-cells. It is primarily used in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma, often in patients who have not responded to other therapies or in combination with chemotherapy. As an intravenous infusion, it is administered in a clinical setting, requiring careful monitoring for infusion-related reactions. Its mechanism of action makes it a targeted therapy for B-cell malignancies, aiming to improve response rates and progression-free survival by selectively eliminating cancerous B-cells while sparing other cell types to a greater extent than traditional chemotherapy.

Uses

• Chronic lymphocytic leukemia (CLL).
• Follicular lymphoma (FL).
• In combination with chemotherapy for B-cell malignancies.
• Patients refractory to other CD20-directed therapies.

Directions For Use

This medication is administered as an intravenous infusion by a healthcare professional in a clinical setting.

Benefits

• Targets CD20-positive B-cells specifically.
• Effective in CLL and follicular lymphoma.
• Can be used in combination with chemotherapy.
• May improve progression-free survival.
• Induces direct cell death of cancer cells.
• Offers a targeted approach to B-cell malignancies.

Side Effects

• Infusion-related reactions (common)
• Neutropenia (low white blood cells)
• Thrombocytopenia (low platelets)
• Anemia
• Fever
• Nausea
• Diarrhea
• Cough
• Upper respiratory tract infection
• Fatigue
• Tumor lysis syndrome (TLS)
• Progressive multifocal leukoencephalopathy (PML) (rare)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol during cancer treatment.
• Pregnancy - Not recommended during pregnancy due to potential fetal B-cell depletion. Effective contraception is required for women of childbearing potential.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose, as the drug may pass into breast milk.
• Liver - Use with caution in patients with severe liver impairment, though specific dose adjustments are not well-established.
• Kidney - No specific dose adjustment is typically required for renal impairment, but caution is advised in severe cases.
• Lung - Patients should be monitored for pulmonary symptoms, as serious respiratory events, including interstitial lung disease, can occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.